Correlating with enhanced tumor growth inhibition, immunization with the DMXAA + 522 adjuvant combination significantly enhanced survival compared to other treatments (vs. DMXAA+: p < 0.001; vs. 522+: p = 0.01; survival comparison using a log-rank test; Figure 5F), further demonstrating the anti-tumor efficacy of the TLR7/8 and STING agonist combination. Here, STING1 is linked to neoplasm.